In vivo CTL Activity Induced by Prime-boost Vaccination using Recombinant Vaccinia Virus and DNA Vaccine Expressing Epitope Specific for CD8+ T Cells

Human respiratory syncytial virus (RSV) is a major cause of respiratory infection in children and in the elderly. The RSV fusion (F) glycoprotein has long been recognized as a vaccine candidate as it elicits cytotoxic T-lymphocyte (CTL) and antibody responses. Two murine H-2Kd-restricted CTL epitopes (F85–93 and F92–106) are known in the F protein of the A2 strain of RSV. F-specific CTL lines using BCH4 fibroblasts that are persistently infected with the Long strain of human RSV as stimulators were generated, and it was found that in this strain only the F85–93 epitope is conserved. Motif based epitope prediction programs and an F2 chain deleted F protein encoded in a recombinant vaccinia virus enabled identification of a new epitope in the Long strain, F249–258, which is presented by Kd as a 9-mer (TYMLTNSEL) or a 10-mer (TYMLTNSELL) peptide. The results suggest that the 10-mer might be a naturally processed endogenous Kd ligand. The CD8+ T-lymphocyte responses to epitopes F85–93 and F249–258 present in the F protein of RSV Long were found to be strongly skewed to F85–93 in in vitro multispecific CTL lines and in vivo during a secondary response to a recombinant vaccinia virus that expresses the entire F protein. However, no hierarchy in CD8+ T-lymphocyte responses to F85–93 and F249–258 epitopes was observed in vivo during a primary response.

Download Full-text

In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1beta*

Surgery ◽

10.1016/s0039-6060(05)80322-8 ◽

1995 ◽

Vol 118 (2) ◽

pp. 185-191 ◽

Cited By ~ 21

Author(s):

G PEPLINSKI ◽

K TSUNG ◽

J MEKO ◽

J NORTON

Keyword(s):

Gene Therapy ◽

Vaccinia Virus ◽

Recombinant Vaccinia Virus ◽

Recombinant Vaccinia ◽

Pancreas Tumor ◽

Interleukin 1Beta

Download Full-text

Involvement of CD8+ T Cells in Delayed-type Hypersensitivity Responses against Bovine Leukemia Virus (BLV) Induced in Sheep Vaccinated with Recombinant Vaccinia Virus Expressing BLV Envelope Glycoprotein

Veterinary Pathology ◽

10.1177/030098589303000202 ◽

1993 ◽

Vol 30 (2) ◽

pp. 104-110 ◽

Cited By ~ 8

Author(s):

K. Okada ◽

S. Ikeyama ◽

K. Ohishi ◽

H. Suzuki ◽

M. Sugimoto ◽

...

Keyword(s):

T Cells ◽

Vaccinia Virus ◽

Envelope Glycoprotein ◽

Bovine Leukemia Virus ◽

Leukemia Virus ◽

Immunohistochemical Analysis ◽

Recombinant Vaccinia Virus ◽

Delayed Type Hypersensitivity ◽

Recombinant Vaccinia ◽

Lymphocytic Infiltrates

Delayed-type hypersensitivity responses against bovine leukemia virus (BLV) envelope glycoprotein (gp60) were induced in the skin of sheep vaccinated with recombinant vaccinia virus (RVV) expressing BLV glycoprotein. The lesions were characterized by marked infiltration of lymphocytes, slight migration of neutrophils, eosinophils, and macrophages in the dermis to hypodermis, and partial intercellular edema in the reticular layer. Immunohistochemical analysis with monoclonal antibodies demonstrated that the lymphocytic infiltrates consisted mainly of CD8+ T cells (53.7–55.8% at 48 hours post-challenge of BLV), CD4+ T cells (24.7–26.7%), and B cells (11.5–16.9%). The role of CD4+ and CD8+ T cells in suppressing BLV growth in RVV-vaccinated animals is discussed.

Download Full-text